Resistin: A Potential Indicator of Aortic Stiffness in Non-Dialysis Chronic Kidney Disease Patients

Chiu-Huang Kuo1,2, Min-Shuo Chen3, Chih-Hsien Wang1,3

  • 1Division of Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan.

Medicina (Kaunas, Lithuania)
|September 28, 2023
PubMed

Insights

In chronic kidney disease (CKD) patients, elevated resistin levels correlate with aortic stiffness. This finding suggests resistin may predict arterial stiffness in individuals with stages 3-5 CKD.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Endocrinology

Background:

  • Resistin is implicated in atherosclerosis development.
  • Chronic kidney disease (CKD) increases cardiovascular morbidity and mortality.
  • Aortic stiffness is a marker of cardiovascular risk.

Purpose of the Study:

  • To investigate the association between serum resistin levels and aortic stiffness.
  • To assess resistin as a predictor of aortic stiffness in CKD patients (stages 3-5).

Main Methods:

  • Serum resistin measured via enzyme immunoassay in 240 CKD patients.
  • Aortic stiffness defined by carotid-femoral pulse wave velocity (cfPWV > 10 m/s).
  • Multivariate regression analyses used to identify predictors.

Main Results:

  • 36.7% of CKD patients had aortic stiffness.
  • Aortic stiffness group showed higher resistin, diabetes, age, weight, BMI, body fat, and blood pressure.
  • Resistin, diabetes, and body weight independently predicted aortic stiffness.

Conclusions:

  • Elevated serum resistin is positively correlated with aortic stiffness in CKD patients.
  • Resistin emerges as a potential biomarker for predicting aortic stiffness in stages 3-5 CKD.